EQT Posts $20bn Galderma Gain

EQT reported a headline $20 billion gain on its Galderma position in a filing published on Apr 22, 2026 (Investing.com). The figure, described by the firm as a record paper gain attributable to the revaluation of its stake, dominated the company's Q1 disclosures and immediately reframed discussions about mark-to-market volatility in private equity portfolios. At the same time, EQT said its fee-generating assets (FGA) for Q1 2026 were essentially unchanged year-on-year, a flat reading that contrasts with the headline revaluation and raises questions about sustainable fee income growth. Institutional investors and allocators are parsing the numbers for implications on carry crystallization, management fee trajectories, and secondary market pricing for large-cap, health-care–sector assets.

Context

EQT's disclosure of a $20bn gain on Galderma on Apr 22, 2026 (Investing.com) arrives against a backdrop of elevated private-market valuations after several uneven public markets cycles. The private equity sector has experienced outsized single-asset revaluations in the last two years, driven by robust corporate earnings in selected sectors, scarcity of high-quality cash-flow-generative assets, and a shift in buyer appetites from leverage-driven deals to strategic, cash-flow-oriented investments. For EQT, a firm with diversified buyout and infrastructure strategies, a single large revaluation such as Galderma can materially distort reported profit and net asset value (NAV) for the quarter even when operational cash flows remain steady.

Quarterly reporting mechanics matter. Private-equity accounting recognises unrealised valuation uplifts when observable buyer prices or credible valuation inputs emerge; however, these uplifts do not immediately translate into fee income unless and until realisations occur or performance fee waterfalls are triggered. EQT's Q1 FGA being flat YoY — as stated in the Apr 22, 2026 disclosure — indicates that assets on which recurring management fees are charged have not meaningfully expanded, despite the one-off valuation event. For limited partners (LPs) and allocators, that divergence between appreciated NAV and static FGA is material because management fee revenue depends more on FGA than on unrealised value increments.

The timing of the disclosure also intersects with a broader calendar of private-market reporting. Several large managers publish quarterly FGA and AUM updates in April, aligning institutional flows and benchmark resets for the second quarter. Investors will therefore compare EQT's flat FGA reading to peers in the same reporting window to assess whether EQT's experience is idiosyncratic or reflective of a sector-wide plateau in fee-generating assets.

Data Deep Dive

The most explicit data point in the company's Apr 22, 2026 filing is the $20bn Galderma gain (Investing.com). The gain is described as a revaluation uplift rather than an immediate cash realisation. That distinction matters: an unrealised gain increases reported NAV and can affect equity valuations, but it does not change the composition of recurring fee revenues unless followed by exits or catch-up fee crystallisation mechanisms. The FGA metric — the pool that determines management fee receipts — was reported as flat for Q1 2026 year-on-year according to the same release. That 0% YoY movement (Investing.com, Apr 22, 2026) stands in contrast to reported NAV volatility.

For context, fee-generating assets are reported differently across managers: some firms include committed capital and uncalled capital in their FGA, while others exclude uninvested dry powder. EQT's disclosure did not suggest a material change in reporting definitions for Q1, meaning the flat reading is likely comparable with prior quarters. When a manager reports a large single-asset revaluation, the market typically looks for accompanying increases in invested capital, new commitments, or realised proceeds that would justify higher future fee flows; those were not evident in EQT's headline Q1 statement.

Comparing performance across peers, managers such as Blackstone and KKR have recently recorded mid-single-digit percentage growth in fee-generated pools over equivalent periods, based on their public quarterly releases. EQT's zero-growth FGA for Q1 2026 therefore sits below an industry-average trend of modest positive growth, a relevant comparative datapoint for allocators weighing relative fee inflation and revenue resilience. (Peer figures referenced are from contemporaneous Q1 2026 public filings by leading global alternative-asset managers.)

Sector Implications

The Galderma revaluation underscores how large strategic assets — particularly in health care and consumer sectors with direct-to-consumer brands — can dramatically swing reported valuations for buyout houses concentrated in those sectors. If such revaluations become more frequent, they could compress the information content of headline NAV movements as indicators of fee revenue and long-term earnings. Allocators may therefore place increased emphasis on FGA growth rates, realised proceeds, and fee-margin disclosures rather than headline NAV uplifts when assessing manager quality.

For European private equity specifically, EQT's situation highlights market bifurcation: a subset of high-quality, resilient businesses can command premium valuations even as broader deal activity and sponsor-to-sponsor M&A remain subdued. That dynamic can widen valuation dispersion across portfolios and create headline gains that are concentrated in a small number of holdings, rather than reflecting broad-based portfolio appreciation. The consequence for LPs is that headline NAV volatility can mask concentrated exposure risks.

From a fundraising and fee-revenue perspective, flat FGA is meaningful. Management fees underpin operating leverage for large alternative-asset managers; if FGA growth stalls, firms become more reliant on performance fees and realised gains to meet revenue and margin expectations. Where a single revaluation accounts for a disproportionate share of reported gains — and those gains are unrealised — firms face a potential mismatch between reported profitability and recurring revenue trajectories.

Risk Assessment

Valuation risk is the most immediate concern. A large unrealised uplift is inherently reversible if subsequent market evidence (e.g., weaker buyer interest, price renegotiations, or sector downgrades) reduces the basis for the valuation. For EQT, the $20bn Galderma gain boosts reported NAV but also places scrutiny on valuation inputs (discount rates, comparables, and forward earnings assumptions). If any of those inputs are later challenged, the reversal could be sharp and attract regulatory and investor scrutiny.

Regulatory and accounting risk should also be considered. Large revaluations in private markets increasingly attract attention from auditors and regulators, particularly when valuations influence performance fee waterfalls and compensation. Scrutiny of valuation governance and mark policies may increase, which can affect the timing and recognition of future uplifts. Institutional investors should therefore assess the transparency of managers' valuation committees and disclosure practices when interpreting headline gains.

Liquidity and concentration risk are related issues. A $20bn uplift tied to a single issuer implies concentration: if the holding represents a large portion of the relevant fund or consolidated balance sheet, a subsequent downturn would have outsized effects. EQT's flat FGA also signals limited growth in the recurring revenue base, creating a risk that operational cash inflows may not be sufficient to stabilise earnings if performance fees fluctuate.

Fazen Markets Perspective

Our assessment is that the Galderma revaluation is a material but ultimately idiosyncratic event for EQT. While headline uplifts can temporarily bolster NAV multiples and investor sentiment, experienced institutional allocators will focus on three durable metrics: (1) the evolution of fee-generating assets over multiple quarters, (2) the ratio of realised to unrealised gains across vintages, and (3) valuation governance transparency. EQT's Q1 FGA reading of 0% YoY growth (Investing.com, Apr 22, 2026) signals that the firm has not yet translated the Galderma uplift into a broader expansion of the fee base. That distinction matters for the sustainability of revenue and for benchmarking EQT against global peers whose fee pools are growing at mid-single-digit rates. Our contrarian view is that periods like this are a good stress-test for LP diligence: managers who can convert headline NAV uplifts into repeatable fee flows and diversified realised exits will separate themselves from peers whose gains are concentrated and transient. For further institutional context on manager metrics and due diligence frameworks, see our topic resources and comparative studies at topic.

FAQ

Q: Does a $20bn unrealised gain mean EQT will recognise equivalent cash profits in the near term?

A: No. Unrealised gains increase NAV but do not immediately create cash inflows. Cash profits require exits or distributions; performance fee waterfalls may only trigger when realised proceeds exceed hurdle rates. Historically, private-equity uplifts often precede multi-quarter realisation processes.

Q: How should LPs treat flat FGA in portfolio construction?

A: Flat FGA suggests stagnant recurring-fee income and places greater reliance on performance fees for manager profitability. LPs should stress-test projected distributions and seek disclosure on fee bases, fee tiering, and expected crystallisation timelines. In historical cycles, managers with diversified FGA growth have shown more predictable revenue streams.

Bottom Line

EQT's $20bn Galderma revaluation is a headline-making NAV event, but the firm's flat Q1 2026 fee-generating assets (0% YoY per Apr 22, 2026 disclosures) temper claims about sustainable fee growth and highlight concentration risks. Institutional allocators should prioritise FGA trends and realised-proceeds visibility when interpreting the earnings impact of large single-asset uplifts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.